ReviewJournal of clinical medicine2024
Myeloid Sarcoma: Novel Advances Regarding Molecular Pathogenesis, Presentation and Therapeutic Options.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Isolated bilateral breast myeloid sarcoma: A rare case report.Radiology case reports · 2026Article
- Blastic Plasmacytoid Dendritic Cell Neoplasm With del(3)(p14p22): Diagnostic Pitfalls and an Uncommon Cytogenetic Finding in a Vietnamese Patient.Journal of cutaneous pathology · 2026Article
- Intracranial Myeloid Sarcoma as the First Manifestation of Acute Monoblastic Leukemia.Journal of neurological surgery reports · 2026Article
- Primary Myeloid Sarcoma of the Breast Mimicking Carcinoma: Aberrant Expression of PAX5 and KMT2A::MLLT10 Fusion.Cureus · 2026Article
- Orbital Myeloid Sarcoma Masquerading as Orbital Cellulitis: A Diagnostic Challenge in an Adult Patient.Cureus · 2026Article
- The Efficiency of Allotransplant in a Case of Acute Biphenotypic Myeloid and B-Lymphoid Leukemia (MPAL Myelo/B NOS) That Presented Concurrently with a Mediastinal Granulocytic Sarcoma Co-Expressing Lymphoid Markers Complicated by Cardiac Tamponade.Diagnostics (Basel, Switzerland) · 2026Article
- Frequent NPM1 mutation, monoblastic/monocytic origin and prognostic significance of organ and system involvement in myeloid sarcoma: a multicenter study.The journal of pathology. Clinical research · 2026Article
- The Outcomes of Myeloid Sarcoma in 64 Pediatric Patients and the Impact of Allogeneic Hematopoietic Stem Cell Transplantation on Treatment Results.Children (Basel, Switzerland) · 2026Article
- A case report of multifocal gastrointestinal myeloid sarcoma without leukemic involvement: an unusual presentation posing a diagnostic challenge.Leukemia research reports · 2026Article
- Clinical and Molecular Characterization of Myeloid Sarcoma: A Systematic Review and Meta-Analysis.Cancers · 2025Review
- Acute Myeloid Leukemia With Extramedullary Infiltration-Gastric Myeloid Sarcoma: A Case Report and Literature Review.Clinical case reports · 2025Article
- Article
- Myeloid sarcoma masquerading as central nervous system diffuse large b-cell lymphoma: a case report and literature review.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid sarcoma (MS), an extramedullary form of acute myeloid leukemia (AML) is a rare tumor mass of myeloid blasts. It can disseminate to any one or multiple anatomical sites, with (synchronous MS) or without (isolated MS) bone marrow (BM) involvement. The aim of this review is to describe the most recent advances in MS regarding diagnosis, molecular background, various clinical manifestations from several organs, and treatment approaches. Due to the lack of prospective, randomized clinical trials, therapeutic decisions are a challenge for the clinician. In the era of novel targeted AML treatments, a critical analysis of how to decide the best option for individual patients, also covering the possible central nervous system (CNS) prophylaxis is provided. For the majority of the patients, AML induction chemotherapy, followed by hematopoietic stem cell transplantation (HSCT) is generally recommended. This paper discusses the role of radiotherapy, the treatment of refractory and relapsed disease, along with the therapeutic approach of difficult-to-treat patients, due to specific problems related to different anatomical sites of MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.